Yondelis I.V. infusion 0.25 mg/1 mg special drug use-results survey (all-case surveillance)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080223101

Enrollment

140

Registered

2016-02-10

Start date

2016-02-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Soft tissue sarcomas

Interventions

investigational material(s) Generic name etc : Yondelis I.V. infusion 0.25 mg/1 mg INN of investigational material : Trabectedin Therapeutic category code : 429 Other antitumor agents Dosage and Admin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients receiving Yondelis

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Safety Logistic regression	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026